Conditions: Lymphoma, Large-Cell, Anaplastic Lymphoma, Non-Hodgkin
Keywords: Antigens, CD30 Antibody-Drug Conjugate Antibodies, Monoclonal Lymphoma, Non-Hodgkin Lymphoma, Large-Cell, Anaplastic monomethyl auristatin E Drug Therapy Immunotherapy Hematologic Diseases Lymphoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 58
Healthy volunteers: no

Brief summary:
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.

Detailed description:

Arms:
arm 1: Brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion

Interventions: intervention 1: brentuximab vedotin
Intervention descriptions: intervention 1: 1.8 mg/kg every 3 weeks by IV infusion

Protocol document: